Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03716050
Other study ID # IRB00038262
Secondary ID
Status Terminated
Phase Phase 2/Phase 3
First received
Last updated
Start date January 30, 2018
Est. completion date March 12, 2019

Study information

Verified date September 2019
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized study using a variety of techniques to compare and examine blood flow to the remaining skin after mastectomy. All treatments being used are considered standard of care and are not experimental. The objective is to compare the techniques and the incidence of perfusion related problems in patient's undergoing mastectomy with immediate breast reconstruction.


Description:

This study's aim is to evaluate and compare a variety of interventions and their effect on the incidence of perfusion related problems in patients with breast cancer undergoing mastectomy and implant-based immediate breast reconstruction (IBR). The ability to identify, prevent and treat these perfusion related problems can help maximize aesthetic results after breast surgery, improve patient satisfaction with both mastectomy and breast reconstruction, and reduce healthcare cost associated with mastectomy and reconstruction complications.The study team will perform a randomized pilot study comprised of eight groups. All of these groups employ accepted techniques, medications and dressings and therefore are not experimental.

Group 1: Breast skin after mastectomy will be clinically examined by the surgeon to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No dye study, ointment, or vacuum dressing will be applied to the breast after implant placement.

Group 2 - Breast skin after mastectomy will be clinically examined by the surgeon, and nitroglycerin (NTG) cream will be applied to the breast skin after implant placement. This cream does not have systemic effects but may improve blood flow to the remnant breast skin after mastectomy.

Group 3 - Breast skin after mastectomy will be clinically examined by the surgeon, and an incisional vacuum-assisted dressing (iVAC) will be placed over the breast incisions after implant placement, which may improve blood flow to the skin and help wound healing.

Group 4 - Breast skin after mastectomy will be clinically examined by the surgeon, and both NTG cream will be applied to the breast skin and an iVAC will be placed over the incisions after implant placement.

Group 5 - Blood flow to breast skin after mastectomy will be examined using a fluorescent dye study called fluorescent angiography (FA) to determine if there is adequate blood flow to the skin to allow safe coverage of the breast implant. No further intervention will be used after implant placement.

Group 6 - Blood flow to breast skin breast skin will be examined using FA, and NTG cream will be applied to the skin after the implant is placed.

Group 7 - Blood flow to breast skin breast skin will be examined using FA, and an iVAC will be placed over breast skin incisions after the implant is placed.

Group 8 - Blood flow to breast skin breast skin will be examined using FA, and both NTG cream and iVAC will be used as interventions after the implant is placed.

The dosage of indocyanine-green (IC-green) to be used for assessment of mastectomy flaps will be in 10 mg boluses, not to exceed 5 mg/kg.

Nitro-Bid® (nitroglycerin ointment, 2%) at a dose of 45 mg (equal to 7.5 cm on the measuring strip provided with packaging) will be used. The paste will be applied to remnant breast skin after skin closure and surgical dressings placed over top.

Incisional negative pressure wound therapy will consist of a standard sponge dressing with adhesive drape, either Ioban® 2 (3M ™) or KCI-V.A.C.® Drape (KCI®), to continuous suction at 125 mm Hg while the patient is in hospital and not to exceed 4 days.

A physician will see the subjects on a regular weekly basis for up to 30 days once the procedure has been completed. These clinical visits are standard of care and the subject's health and well-being will be monitored rigorously during these visits. If during any of these visits, the physician deems a therapy necessary to prevent impairment/damage and improve well-being, the subject will be treated appropriately.


Recruitment information / eligibility

Status Terminated
Enrollment 17
Est. completion date March 12, 2019
Est. primary completion date March 12, 2019
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria:

- Patients must be female.

- Patients must be between the ages of 18 and 99 years.

- Patients must undergo mastectomy with our attending breast oncology surgeons followed by possible implant-based immediate breast reconstruction (IBR) performed by our attending plastic surgeons at WFBMC.

- Patients must have the ability to understand and the willingness to sign an IRB-approved informed consent document.

Exclusion Criteria:

- Patients who are under the age of 18 or over the age of 99.

- Patients who are undergoing mastectomy without immediate breast reconstruction including immediate breast reconstruction with autologous tissue (or combination of autologous tissue with tissue expanders or implants), or patients with a history of mastectomy presenting for delayed breast reconstruction.

- Patients with pre-existing conditions in which use of indocyanine-green is contraindicated or must be used with caution, including those with a history of allergy to iodides or iodinated dye, those with chronic kidney disease, those with hepatic failure or cirrhosis of the liver, and females who are nursing, pregnant, or may become pregnant.

- Pregnant women are excluded from this study because pregnancy precludes immediate breast reconstruction in our patient population.

- Patients with pre-existing conditions in which use of nitroglycerin paste is contraindicated, including those with a history of cardiac insufficiency, hypotension, sensitivity to nitrites, severe liver impairment, glaucoma, hyperthyroidism, recent head trauma, severe anemia, or taking certain medication (i.e. alteplase, aspirin, beta-blocker, calcium channel blocker, diuretics or thiazides).

- Patients with pre-existing conditions in whom use of incisional negative pressure wound therapy is contraindicated including those with evidence of surgical site infection ( i.e. erythema, purulent drainage), clinical signs of hematoma (i.e. wound swelling, fluctuance, blood drainage), history of persistent cancer, exposed blood vessel on site of proposed therapeutic use, or sensitivity to acrylics and adhesives.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nitroglycerin
Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 2,4,6, and 8 will include Nitroglycerin cream.
Device:
Negative Pressure Wound Therapy/ Wound VAC
Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 3,4,7,and 8 will receive iVAC therapy.
Other:
Fluorescent Angiography with indocyanine-green (not to exceed 5mg/kg)
Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 5,6,7,and 8 will receive angiography.
No treatment
Patient's will be randomized into one of eight groups and receive the intended treatment specified for that particular group. Groups 1 will include no treatment.

Locations

Country Name City State
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Wake Forest University Health Sciences

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Soft Tissue Ischemia/Loss Number of partial and full thickness soft tissue defects identified postoperatively in clinic follow up Up to 30 days
Primary Number of Participants With Surgical Site Infection Number of Participants with soft tissue cellulitis or abscess identified postoperatively either clinically or with wound culture Up to 30 days
Primary Number of Participants With Delayed Wound Healing manifesting as suture dehiscence and opening of an incisional wound Up to 30 days
Secondary Number of Participants With Operative Intervention Secondary to Perfusion Related Problems Up to 30 days
Secondary Number of Participants Requiring Outpatient Prescription for Antibiotics or Requiring Hospital Admission for IV Antibiotics Up to 30 days
Secondary Number of Participants Requiring Wound Care Management Modalities for Treatment of Delayed Wound Healing Complications up to 30 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03281707 - NIRS and DO2i Correlation N/A
Completed NCT03001531 - Safety and Tolerance of Local Heat Application in the Paralyzed Area of Patients With Complete Paraplegia N/A
Recruiting NCT05492968 - The Effect of Epinephrine, Norepinephrine and Phenylephrine on Intraoperative Hemodynamic Performance Phase 4
Completed NCT04144166 - Evaluation of Capillary Refill Index
Completed NCT04081974 - Prevalence and Predictors of Distal Limb Ischemia in Minimally Invasive Cardiac Surgery.
Recruiting NCT03747731 - A Non-invasive Evaluation of Kidney-Lung Interactions
Recruiting NCT06254833 - Microdosing ICG for Serial Colonic Perfusion Study During Surgery N/A
Completed NCT03860493 - Feasibility of the IC-Flow Device for Fluorescent Perfusion Evaluation During Feasibility of the IC-Flow Device
Completed NCT03711916 - Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery N/A
Not yet recruiting NCT06077396 - Does Radial Artery Cannulation Affect the Perfusion Index(PI) of the Hand in Liver Transplant Operations? N/A
Not yet recruiting NCT04907071 - Intravascular Ultrasound for the Evaluation of Malperfusion Syndrome in the Setting of Acute Aortic Dissection N/A
Recruiting NCT04424069 - OCTA Analysis of Macular and Papillary Perfusion After Refractive Surgery in Myopes N/A
Recruiting NCT05276167 - Hyperthermic Intravesical Perfusion for Muscle-invasive Bladder Urothelial Carcinoma N/A
Terminated NCT03715270 - Evaluation of Tissue Oxygen Levels During Breast Reconstruction With a New Surgical Device
Recruiting NCT06019546 - PErfusion QUality ODds
Recruiting NCT04929873 - Clinical Study of VA-ECMO Remote Limb Re-perfusion Monitoring Technology N/A
Recruiting NCT06047158 - Effects of Omega-3 Fish Oil Fat Emulsion on Rehabilitation and Immune Function After Radical Surgery Combined With Intraperitoneal Hyperthermic Infusion Chemotherapy in Patients With Locally Advanced Gastric Cancer
Active, not recruiting NCT05517044 - The Pre-acclimatization Augmented Extreme Altitude Expedition N/A
Terminated NCT03843307 - Avazzia-University of Texas Southwestern Medical Center-Tennant Biomodulator® PRO Perfusion Study N/A
Completed NCT06405282 - Weightlessness Associated Cephalad Fluid Shifts; The Potential to Evaluate Venous and Lymphatic Dysfunction